WallStreetZenWallStreetZen

NASDAQ: HOWL
Werewolf Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HOWL

Based on 3 analysts offering 12 month price targets for Werewolf Therapeutics Inc

Min Forecast
$3.00+127.27%
Avg Forecast
$8.00+506.06%
Max Forecast
$15.00+1,036.36%

Should I buy or sell HOWL stock?

Based on 3 analysts offering ratings for Werewolf Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although HOWL's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates HOWL as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their HOWL stock forecasts and price targets.

HOWL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-21
lockedlocked$00.00+00.00%2025-05-09
lockedlocked$00.00+00.00%2025-03-12

1 of 1

Forecast return on equity

Is HOWL forecast to generate an efficient return?

Company
-181.14%
Industry
123.99%
Market
-49.26%
HOWL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HOWL forecast to generate an efficient return on assets?

Company
-81.14%
Industry
47.19%
HOWL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HOWL earnings per share forecast

What is HOWL's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.82
Avg 2 year Forecast
-$1.58
Avg 3 year Forecast
-$1.85

HOWL revenue forecast

What is HOWL's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$6.0M
Avg 2 year Forecast
$50.0M
Avg 3 year Forecast
$9.3M

HOWL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HOWL$1.32$8.00+506.06%Buy
ACET$0.73$5.50+656.53%Strong Buy
AKTX$0.92$5.00+442.89%Strong Buy
IMMX$2.19$7.00+219.63%Buy
ANL$1.68N/AN/A
View Top Biotech Stocks

Werewolf Therapeutics Stock Forecast FAQ

Is Werewolf Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: HOWL) stock is to Buy HOWL stock.

Out of 3 analysts, 0 (0%) are recommending HOWL as a Strong Buy, 3 (100%) are recommending HOWL as a Buy, 0 (0%) are recommending HOWL as a Hold, 0 (0%) are recommending HOWL as a Sell, and 0 (0%) are recommending HOWL as a Strong Sell.

If you're new to stock investing, here's how to buy Werewolf Therapeutics stock.

What is HOWL's earnings growth forecast for 2025-2027?

(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Werewolf Therapeutics's earnings in 2025 is -$73,144,000.On average, 5 Wall Street analysts forecast HOWL's earnings for 2025 to be -$83,043,862, with the lowest HOWL earnings forecast at -$118,438,107, and the highest HOWL earnings forecast at -$67,678,919. On average, 5 Wall Street analysts forecast HOWL's earnings for 2026 to be -$72,251,818, with the lowest HOWL earnings forecast at -$126,669,327, and the highest HOWL earnings forecast at -$36,583,199.

In 2027, HOWL is forecast to generate -$84,484,326 in earnings, with the lowest earnings forecast at -$111,121,468 and the highest earnings forecast at -$60,362,279.

What is HOWL's revenue growth forecast for 2025-2027?

(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Werewolf Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast HOWL's revenue for 2025 to be $274,373,994, with the lowest HOWL revenue forecast at $274,373,994, and the highest HOWL revenue forecast at $274,373,994. On average, 1 Wall Street analysts forecast HOWL's revenue for 2026 to be $2,286,449,950, with the lowest HOWL revenue forecast at $2,286,449,950, and the highest HOWL revenue forecast at $2,286,449,950.

In 2027, HOWL is forecast to generate $425,279,691 in revenue, with the lowest revenue forecast at $425,279,691 and the highest revenue forecast at $425,279,691.

What is HOWL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: HOWL) forecast ROA is -81.14%, which is lower than the forecast US Biotechnology industry average of 47.19%.

What is HOWL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year HOWL price target, the average HOWL price target is $8.00, with the highest HOWL stock price forecast at $15.00 and the lowest HOWL stock price forecast at $3.00.

On average, Wall Street analysts predict that Werewolf Therapeutics's share price could reach $8.00 by Aug 21, 2026. The average Werewolf Therapeutics stock price prediction forecasts a potential upside of 506.06% from the current HOWL share price of $1.32.

What is HOWL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: HOWL) Werewolf Therapeutics's current Earnings Per Share (EPS) is -$1.64. On average, analysts forecast that HOWL's EPS will be -$1.82 for 2025, with the lowest EPS forecast at -$2.59, and the highest EPS forecast at -$1.48. On average, analysts forecast that HOWL's EPS will be -$1.58 for 2026, with the lowest EPS forecast at -$2.77, and the highest EPS forecast at -$0.80. In 2027, HOWL's EPS is forecast to hit -$1.85 (min: -$2.43, max: -$1.32).

What is HOWL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: HOWL) forecast ROE is -181.14%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.